TAU-Stanford-UCSF/Gladstone-Buck Institutes Symposium

Toward Personalized Diagnosis and Drug Screening

Celebrating the Taube-Koret Global Collaboration in Neurodegenerative Diseases

Sunday, Jan 12, 2020
Steinhardt Museum of Natural History, Tel Aviv University

9:00  Coffee
9:30  OPENING: Dean Abdussalam Azem, Karen B. Avraham, Uri Ashery, Harvey Cohen
9:45  Matthew Porteus, Stanford University
      Genetic engineering to create reagents to treat and understand Huntington’s Disease
10:30 Miguel Weil, Tel Aviv University
      Establishment of a personalized diagnosis and drug screening system for patients with Huntington’s disease
11:00 Uri Ashery, Tel Aviv University
      Identifying alpha-synuclein aggregation using super-resolution microscopy: challenges and future directions
11:30 Frank Longo, Stanford University
      Small molecule modulation of neurodegenerative signaling in Huntington’s Disease: Morphological-behavioral-biomarker outcomes
12:15 Light lunch
13:00  ROUNDTABLE: What pieces are we missing to cure Huntington’s Disease?
      Moderated by Dean Ehud Grossman
13:15  Hagit Eldar-Finkelman, Tel Aviv University
      Discovery and design of novel GSK-3 inhibitors for treating neurodegenerative disorders
13:45  Steve Finkbeiner, UCSF-Gladstone Institutes
      Finding therapeutic targets and treatments for neurodegenerative disease with patient-derived stem cells, robotics and artificial intelligence
14:30  Dan Frenkel, Tel Aviv University
      Targeting the role of astrocytes cellular senescence in the progression of neurodegenerative diseases
15:00  Lisa Ellerby, Buck Institute
      Modeling Huntington’s Disease with induced pluripotent stem cells
15:45  Avi Ashkenazi, Tel Aviv University
      Identifying modulators of alpha synuclein levels and toxicity via ubiquitin signaling
16:15  Blavatnik Drug Discovery Center Tour

Pre-registration requested